The GLP category contains some of the most-studied compounds in metabolic research. All act on incretin and related receptor systems, but they differ in which receptors they target — and that distinction is the whole story.
Single, dual, and triple agonists
Semaglutide is a GLP-1 receptor agonist — a single-target compound with an extended half-life (~7 days in research characterizations). Tirzepatide is a dual GIP/GLP-1 receptor agonist, adding a second receptor target. Retatrutide goes further as a triple GLP-1/GIP/glucagon receptor agonist — the most-researched GLP compound of 2024–2025.
Amylin analogues
Cagrilintide is a long-acting amylin analogue, frequently studied in combination with semaglutide (referred to in literature as CagriSema). It represents a different mechanistic lever within the same broad research area.
Why the receptor target matters
For research, the receptor profile defines the experimental question. A single-agonist study isolates one pathway; dual and triple agonists let researchers examine combined receptor activity. None of this speaks to outcomes — it is a map of mechanism, which is what reproducible research depends on.
Every GLP compound ships with an independent, lot-matched HPLC COA you can verify by lot number; see what an HPLC COA proves. All compounds are research reference materials for laboratory research use only. Not for human consumption.